---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-021506"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:57:28.733220+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to Board of Directors

## Summary
- Stuart Duty and Neil Gallagher appointed effective May 1, 2025 as Class II directors.
- Each granted initial option to purchase 50,000 shares vesting over three years.
- Duty to serve on Audit Committee; Gallagher on Science Committee.
- Duty receives annual cash retainers $40,000 board + $7,500 audit; Gallagher $40,000 + $5,000 science.
- Audit Committee now has three independent members, regaining Nasdaq compliance.

## SEC filing metadata
- accession: 0001628280-25-021506
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/fhtx-20250425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-021506
- JSON: https://secwatch.observer/filing/0001628280-25-021506.json
- Plain text: https://secwatch.observer/filing/0001628280-25-021506.txt

## Key facts
- Executive change
  Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm
- Executive change
  Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Stuart Duty to the Board, effective May 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/0001628280-25-021506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.